希罗达在转移性乳腺癌维持治疗中的疗效观察  

The observation of capecitabine in the maintenance treatment of metastatic breast cancer

作　　者：赵韬[1] 邵清[1] 张汀荣[1] 赵臻[1] 殷华芳[1] 陆向东[1] 

机构地区：[1]东南大学附属江阴市人民医院肿瘤三科,江苏江阴214400

出　　处：《实用临床医药杂志》2011年第7期88-90,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨希罗达在转移性乳腺癌(MBC)维持治疗中的疗效及安全性。方法已进行6～8周期一线治疗的患者65例,根据治疗方法不同分为实验组与对照组。实验组(n=45)患者给予希罗达800～1000 mg/m^2,每日2次,持续给药。对照组(n=20)患者不接受希罗达维持治疗,以观察为主。观察比较两组患者总生存率(OS),无进展生存率(PFS),完全缓解(CR),部分缓解(PR),总有效率(RR)与安全性。结果与实验组比较,对照组进展概率增加的更加明显,无进展概率及累计无进展生存率降低更明显。但两组各时间段的累计无进展生存率比较,差异无统计学意义(P>0.05)。各时间段实验组OS明显高于对照组,但差异无统计学意义(P>0.05)。实验组治疗的总有效率高于对照组(P<0.05),不良反应发生率高于对照组。结论在一线治疗结束后给予的延长治疗,希罗达可以显著延长患者生存时间,提高临床治疗效果,但不良反应发生率较高。Objective To explore the efficacy and safety of Capecitabine in the maintenance treatment of metastatic breast cancer（MBC）.Methods Sixty - five patients,who have been carried out 6 to 8 cycles of first - line treatment,were divided into experimental group and control group according to the different treatment methods.Within the experimental group（n = 45）,patients were given Capecitabine 800～1 000 mg/m^2,bid with sustained drug delivery.Within the control group（n = 20）,the effect was observed and Capecitabine maintenance therapy was not given. The OS,PFS,CR,PR,RR and security in these two groups were observed and compared. Results Compared with the experimental group,the probability of progress,no progress and the cumulative probability of progression - free survival rate were reduced even more apparently in control group.But each time,the cumulative progression - free survival difference was not statistically significant in the two groups（P0.05）.The OS time was significantly higher in the experimental group,but the difference was not statistically significant（P0.05）.In the experimental group, the RR was significantly higher than the control group（P0.05）.Conclusion In the extension treatment,Capecitabine can significantly prolong survival time and improve clinical effect,but there is a higher incidence of adverse reactions.

关 键 词：乳腺癌 转移性 希罗达 安全性 

分 类 号：R737.9[医药卫生—肿瘤]